US FDA gives mixed review for Depomed, Noven hot flash drugs
This article was originally published in Scrip
Executive Summary
While suicidality was the greatest safety concern for the FDA in its reviews of Depomed's and Noven Pharmaceuticals’ experimental medicines for treating moderate-to-severe menopausal-related hot flashes and night sweats, a condition known as vasomotor symptoms (VMS), agency reviewers noted that risk already is known about the active ingredients in both drugs, with the scientists raising only moderate concerns about other adverse events (AEs) in the companies' studies.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.